|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PTENP1 transcript was expressed in NE, cell lines, and 34/61 (56%) primary tumors.
|
22005521 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTENP1 is a pseudogene of the PTEN tumor suppression gene (TSG).
|
25249556 |
2014 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PTENP1 and PTEN are direct targets of miRNA miR21 and their expression is suppressed by miR21 in ccRCC cell lines. miR21 expression promotes ccRCC cell proliferation, migration, invasion in vitro, and tumor growth and metastasis in vivo.
|
25249556 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTENP1, a pseudogene of PTEN, was previously reported to be a tumour suppressor in some cancer types.
|
28112249 |
2017 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
PTENP1 performed a negative role in the development of BC via downregulating miR-19 probably through the PTEN/PI3K/Akt pathway.
|
29212574 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PTENP1 performed a negative role in the development of BC via downregulating miR-19 probably through the PTEN/PI3K/Akt pathway.
|
29212574 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
PTENP1, a long noncoding RNA, has previously been reported to be involved in tumorigenesis and cancer progression.
|
30229832 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PTENP1, a long noncoding RNA, has previously been reported to be involved in tumorigenesis and cancer progression.
|
30229832 |
2018 |
|
HER2-positive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A target prediction analysis coupled with in vitro and in vivo validations revealed that miR-21 levels inversely correlated with the expression of PTEN (rs = -0.502; p = 0.005) and PDCD4 (rs = -0.426; p = 0.019), which differentially influenced the drug sensitivity of HER2-positive breast cancer cells.
|
26452030 |
2015 |
|
Squamous cell carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Also, the homogeneous relationship between expression of PTENp1 and PTEN was confirmed in OSCC tumor xenografts.
|
27862321 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a model for the protein-coding-independent role of RNAs, we describe the functional relationship between the mRNAs produced by the PTEN tumour suppressor gene and its pseudogene PTENP1 and the critical consequences of this interaction.
|
20577206 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Detection of PTEN nonsense mutation and psiPTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay.
|
10980610 |
2000 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Enhanced PTENP1 could inhibit BC cell growth, metastasis and tumourigenicity by inhibiting miR-19b and facilitating PTEN in BC, thereby may represent a novel target for diagnosis and treatment of BC.
|
28731027 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Enhanced PTENP1 could inhibit BC cell growth, metastasis and tumourigenicity by inhibiting miR-19b and facilitating PTEN in BC, thereby may represent a novel target for diagnosis and treatment of BC.
|
28731027 |
2017 |
|
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma.
|
30584245 |
2018 |
|
Macrocephaly
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exome sequencing of the family also identified a rare inherited variant predicted to disrupt splicing of TPTE / PTEN2, a PTEN homologue, which may likewise contribute to both macrocephaly and autism risk.
|
26076356 |
2015 |
|
Autistic Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exome sequencing of the family also identified a rare inherited variant predicted to disrupt splicing of TPTE / PTEN2, a PTEN homologue, which may likewise contribute to both macrocephaly and autism risk.
|
26076356 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Exosomal PTENP1 could suppress tumor growth in vivo.
|
30285771 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Exosomes derived from normal cells transfer PTENP1 to BC cells, which reduce the progression of BC both in vitro and in vivo and suggest that exosomal PTENP1 participates in normal-cell-to-bladder-cell communication during the carcinogenesis of BC.
|
30285771 |
2018 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
For example, we find multiple known (e.g., miR-20a-PTEN-PTENP1) and novel (e.g., miR-375-SOX15-PPP4R1L) microRNA-gene-pseudogene associations in prostate cancer.
|
31029062 |
2019 |
|
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
For example, we find multiple known (e.g., miR-20a-PTEN-PTENP1) and novel (e.g., miR-375-SOX15-PPP4R1L) microRNA-gene-pseudogene associations in prostate cancer.
|
31029062 |
2019 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Further studies are needed to evaluate the impact of PTEN/PTENP1/miRNA interactions on tumorigenesis regulation in EMCA.
|
22005521 |
2012 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, the invasion and migration abilities of SHG44 and U251 cells were reduced after being transfected with a PTENP1 overexpression plasmid.
|
30613153 |
2019 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
G allele of rs7853346 polymorphism in PTENP1 enhances the proliferation of multiple myeloma cancer stem cells by promoting the expression of PTENP1 and its downstream signaling molecules.
|
31338886 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
GeneticVariation
|
group |
BEFREE |
G allele of rs7853346 polymorphism in PTENP1 enhances the proliferation of multiple myeloma cancer stem cells by promoting the expression of PTENP1 and its downstream signaling molecules.
|
31338886 |
2019 |